Back to search results
NCT06027255

Long COVID Immune Profiling

Active, Not Recruiting
NAAges 18+InterventionalDiagnostic
Vanderbilt University Medical Center
~150 participants
Updated 2026-07-15 on ClinicalTrials.gov
What's tested:IL-6cytokines (IL-17, and IFN-ɣ)Compass 31

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
IL-6 levels
Measured over Baseline

Conditions

Long COVID
POTS - Postural Orthostatic Tachycardia Syndrome
Autonomic Dysfunction

Explore related trials

COVID-19 InfectionDisorder of autonomic nervous systemOrthostatic IntolerancePost-Acute Sequelae of COVID-19Postural Orthostatic Tachycardia Syndrome

NCT06027255

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Cyndya Shibao

    Nashville, Tennesseeno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subjects will be 18 years or older, men and women.
History of confirmed COVID-19 infection (positive contact and symptoms, antigen test or PCR).
POTS will be defined as the presence of orthostatic tachycardia (\>30 bpm) and chronic (\>3 months) pre-syncopal symptoms.
Post-COVID-19 POTS will be defined as the presence of orthostatic tachycardia (\>30 bpm) and chronic (\>3 months) pre-syncopal symptoms. Symptoms occurred within 2 months after COVID infection and persistent until enrollment in the study.

Exclusion

Individuals with a history of physician diagnosed myocardial infarction, angina, heart failure, stroke, or transient ischemic attack, or who had undergone an invasive procedure for CVD (coronary artery bypass graft, angioplasty, valve replacement, pacemaker placement or other vascular surgeries).
Inability to comply with the protocol, e.g. uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.
Chronic use of steroids, anti-IL6 (omalizumab), anti-TNF-alpha, other immunosuppressants.
Chronic use of NSAID. Should not enroll if taking without one week prior to blood sampling.
Treatment with plasmapheresis, IVIG or other immune modulator

What this trial measures

  • IL-6 levelsBaseline

    Parasympathetic (PNS) function, protects against inflammation. To Evaluate level of inflammation in post-COVID-19 POTS and patients with history of COVID-19 infection without sequelae and correlate this with the degree of decreased PNS activity. The primary endpoint is IL-6 levels